[go: up one dir, main page]

TR200200789T2 - Farmasötik olarak aktif sülfonamid türevleri. - Google Patents

Farmasötik olarak aktif sülfonamid türevleri.

Info

Publication number
TR200200789T2
TR200200789T2 TR2002/00789T TR200200789T TR200200789T2 TR 200200789 T2 TR200200789 T2 TR 200200789T2 TR 2002/00789 T TR2002/00789 T TR 2002/00789T TR 200200789 T TR200200789 T TR 200200789T TR 200200789 T2 TR200200789 T2 TR 200200789T2
Authority
TR
Turkey
Prior art keywords
sulfonamide derivatives
substituted
formula
present
pharmaceutically active
Prior art date
Application number
TR2002/00789T
Other languages
English (en)
Inventor
Arkinstall Stephen
Halazy Serge
Church Dennis
Camps Montserrat
Rueckle Thomas
Gotteland Jean-Pierre
Biamonte Marco
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of TR200200789T2 publication Critical patent/TR200200789T2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut bulus, özellikle farmasötik olarak aktif bilesikler olarak formül I'in sülfonamid türevleri yani sira bu gibi sülfonamid türevlerini ihtiva eden farmasötik formülasyonlar ile ilgilidir. Bahsedilen sülfonamid türevleri JNK yolunun etkili modülatörleri olup, özellikle JNK 2 3'ün etkili ve selektif inhibitörleridir. Mevcut bulus, ayrica yeni sülfonamid türevleri yani sira bunlarin hazirlanmalari ile de ilgilidir. Uygun farmasötik ajanlar olarak, mevcut bulusa uygun formül I'in bilesikleri olup, içerisideki, Ar1 ve Ar2, birbirinden bagimsiz, ikameli ya da ikamesiz aril ya da hetaroil gruplari, X,O ya da S, tercihen O; R1, hidrojen ya da bir C1-C6-alkil grubudur ya da R1,Ar1'e sahip bir ikameli ya da ikamesiz 5-6 üyeli doymus ya da doymamis halka meydana getirir; N,O ila 5 arasinda, tercihen 1-3 arasinda bir tamsayi ve en çok terihen 1'dir; formül I içindeki Y, en az bir nitrojen atomu ihtiva eden bir ikamesiz ya da bir ikameli 4-12-üyeli doymus siklik ya da bisiklik alkildir ki bu
TR2002/00789T 1999-09-28 2000-09-28 Farmasötik olarak aktif sülfonamid türevleri. TR200200789T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99810869A EP1088821A1 (en) 1999-09-28 1999-09-28 Pharmaceutically active sulfonamide derivatives

Publications (1)

Publication Number Publication Date
TR200200789T2 true TR200200789T2 (tr) 2002-08-21

Family

ID=8243049

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00789T TR200200789T2 (tr) 1999-09-28 2000-09-28 Farmasötik olarak aktif sülfonamid türevleri.

Country Status (30)

Country Link
US (1) US8012995B1 (tr)
EP (2) EP1088821A1 (tr)
JP (2) JP5015397B2 (tr)
KR (1) KR100827533B1 (tr)
CN (1) CN1189467C (tr)
AR (1) AR031531A1 (tr)
AT (1) ATE309998T1 (tr)
AU (1) AU777708B2 (tr)
BG (1) BG65797B1 (tr)
BR (1) BR0014641A (tr)
CA (1) CA2379575C (tr)
CZ (1) CZ2002880A3 (tr)
DE (1) DE60024115T2 (tr)
DK (1) DK1218374T3 (tr)
EA (1) EA005368B1 (tr)
EE (1) EE05109B1 (tr)
ES (1) ES2248114T3 (tr)
HK (1) HK1048306B (tr)
HU (1) HUP0203312A3 (tr)
IL (2) IL148876A0 (tr)
MX (1) MXPA02003199A (tr)
NO (1) NO324792B1 (tr)
NZ (1) NZ517424A (tr)
PL (1) PL212237B1 (tr)
SI (1) SI1218374T1 (tr)
SK (1) SK287058B6 (tr)
TR (1) TR200200789T2 (tr)
UA (1) UA74796C2 (tr)
WO (1) WO2001023378A1 (tr)
ZA (1) ZA200201509B (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1193267A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
EP1193268A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
BR0116063A (pt) * 2000-12-13 2004-08-03 Wyeth Corp Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
KR20040007497A (ko) 2001-04-16 2004-01-24 에자이 가부시키가이샤 신규 1h-인다졸 화합물
WO2003010164A1 (en) * 2001-07-23 2003-02-06 Applied Research Systems Ars Holding N.V. Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
SG143986A1 (en) 2002-06-11 2008-07-29 Wyeth Corp Substituted phenylsulfonamide inhibitors of beta amyloid production
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
AU2004221812B2 (en) 2003-03-19 2010-02-18 Exelixis Inc. Tie-2 modulators and methods of use
CA2517155A1 (en) 2003-03-31 2004-10-28 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
ES2385219T3 (es) 2003-09-12 2012-07-19 Merck Serono Sa Derivados de sulfonamida para el tratamiento de diabetes
EP1709003B1 (en) 2004-01-16 2009-09-23 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
WO2005074921A1 (en) * 2004-02-09 2005-08-18 University Of Zurich Treatment of atherosclerosis
CN1660811A (zh) * 2004-02-27 2005-08-31 中国科学院上海药物研究所 1,4-二取代苯类化合物及其制备方法和用途
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
CA2571124A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 jnk 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
AU2011265521B8 (en) * 2005-07-15 2014-05-22 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
JP2009538882A (ja) * 2006-06-02 2009-11-12 メルク セローノ ソシエテ アノニム 皮膚疾患の治療のためのjnk阻害物質
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1706174A3 (ru) * 1989-02-08 1995-10-10 Институт биохимии Литовской АН N-замещенные 5-фталимидонафталин-1-сульфамиды в качестве полупродуктов для получения n-замещенных аминонафталинсульфамидов
EP0594593A1 (en) 1990-03-15 1994-05-04 PHARMACIA & UPJOHN COMPANY Therapeutically useful heterocyclic indole compounds
US5106983A (en) 1990-04-30 1992-04-21 The United States Of America As Represented By The Secretary Of The Army Process of making carfentanil and related analgesics
US5576313A (en) 1994-08-29 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5684013A (en) * 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
WO1997036861A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Meta-substituted phenylene sulphonamide derivatives
CN1159292C (zh) * 1996-05-31 2004-07-28 法玛西雅厄普约翰美国公司 用作选择性多巴胺d3配体的芳基取代的环胺类化合物
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CN1330638A (zh) * 1998-11-25 2002-01-09 默克专利股份公司 取代的苯并[de]异哇啉-1,3-二酮
AU7031500A (en) * 1999-09-23 2001-04-24 Astrazeneca Ab Therapeutic quinazoline compounds
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
IL148876A (en) 2010-11-30
CN1377347A (zh) 2002-10-30
CZ2002880A3 (cs) 2002-06-12
NO324792B1 (no) 2007-12-10
EA200200417A1 (ru) 2002-10-31
AU7307400A (en) 2001-04-30
BR0014641A (pt) 2002-06-11
MXPA02003199A (es) 2002-10-31
CA2379575A1 (en) 2001-04-05
PL354169A1 (en) 2003-12-29
SK5802002A3 (en) 2002-08-06
JP5015397B2 (ja) 2012-08-29
EP1218374B1 (en) 2005-11-16
EP1088821A1 (en) 2001-04-04
JP2012121904A (ja) 2012-06-28
SK287058B6 (sk) 2009-10-07
ZA200201509B (en) 2003-04-30
SI1218374T1 (sl) 2006-02-28
BG65797B1 (bg) 2009-12-31
DK1218374T3 (da) 2005-12-27
DE60024115D1 (de) 2005-12-22
EE05109B1 (et) 2008-12-15
HK1048306A1 (en) 2003-03-28
ATE309998T1 (de) 2005-12-15
NO20021530D0 (no) 2002-03-26
EP1218374A1 (en) 2002-07-03
EA005368B1 (ru) 2005-02-24
WO2001023378A1 (en) 2001-04-05
KR20020062282A (ko) 2002-07-25
HUP0203312A2 (hu) 2003-01-28
ES2248114T3 (es) 2006-03-16
AU777708B2 (en) 2004-10-28
BG106527A (en) 2003-02-28
AR031531A1 (es) 2003-09-24
US8012995B1 (en) 2011-09-06
JP2003510319A (ja) 2003-03-18
HUP0203312A3 (en) 2003-02-28
DE60024115T2 (de) 2006-07-27
UA74796C2 (en) 2006-02-15
IL148876A0 (en) 2002-09-12
KR100827533B1 (ko) 2008-05-06
PL212237B1 (pl) 2012-08-31
EE200200165A (et) 2003-04-15
NO20021530L (no) 2002-03-26
CN1189467C (zh) 2005-02-16
HK1048306B (zh) 2005-06-10
CA2379575C (en) 2011-03-15
NZ517424A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
TR200200789T2 (tr) Farmasötik olarak aktif sülfonamid türevleri.
YU21803A (sh) Farmaceutski aktivni derivati sulfonamida koji imaju i lipofilne i jonizujuće osobine kao inhibitori protein-junkinaza
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1120189T1 (el) Λιπιδια, συμπλοκα λιπιδιων και χρηση εξ' αυτων
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
HUP9903766A2 (en) Pyridyl alkene- and pyridyl alkine- acid amides, use of them as cytostatics and immunosuppressives, process for their preparation and pharmaceuticals containing the same
TR200201509T2 (tr) Farmasötik olarak aktif benzazol türevleri.
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
HUP0300641A2 (hu) Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
BR9815377A (pt) Derivados de sulfonil
TR200201102T2 (tr) Yeni oligosakkaritler, bunların hazırlanması ve bunları içeren ilaç bileşimleri
TR199901933T1 (tr) 3-Piperidil-4-oksokuinazolin türevleri ve bunlari içeren farmasötik terkipler.
TR200102038T2 (tr) Amid bileşenler
EA200201201A1 (ru) Соединения с сульфамидной группой и содержащие эти соединения фармацевтические композиции
EA200100983A1 (ru) Производные 13-метилэритромицина
PT623133E (pt) Compostos de aminoalquilo substituidos
TR200200436T2 (tr) Yeni makrolit antibiyotikler
DE69524428D1 (de) Dihydrobenzofuran und verwandte verbindungen als entzündungshemmende mittel
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
HUP0303636A2 (hu) Dihidronaftalin-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
HUP9904210A2 (hu) Kamptotecin-analógok, alkalmazásuk gyógyszerként és ilyen vegyületeket tartalmazó gyógyászati készítmények
FI930171A0 (fi) Piperidinfoereningar, framstaellning och anvaendning av dessa
ATE195517T1 (de) Chinolinonderivate und diese enthaltende antiallergische zusammensetzungen
ATE119910T1 (de) Amphotericin b derivate.